DESCARGAR
VERSIÓN EXTENSA
DESCARGAR
VERSIÓN CORTA
DESCARGAR RECOMENDACIONES Y FLUJOGRAMAS
vacio
vacio
Ámbito
- Esta guía debe ser usada en todos los establecimientos del seguro social del Perú (EsSalud), según lo correspondiente a su nivel de atención.
Población y alcance
- Población: pacientes con síndrome coronario agudo.
- Alcance: diagnóstico y manejo de pacientes con síndrome coronario agudo.
Autores
Expertos clínicos:
- David German Gálvez Caballero
INCOR, EsSalud - Carmen Patricia Rebaza Miyasato
INCOR, EsSalud - Christian Nolte Rickards
INCOR, EsSalud - Walter Alberto Alarco León
INCOR, EsSalud
Metodólogos:
- Adrián V. Hernández
Consultor del IETSI, EsSalud - Alejandro Piscoya
Consultor del IETSI, EsSalud
Coordinadores:
- Víctor Suárez Moreno
IETSI, EsSalud - Raúl Timaná Ruiz
IETSI, EsSalud
Descargar PDF con más información sobre la filiación y rol de los autores.
Metodología
Resumen de la metodología:
- Conformación del GEG: La Dirección de Guías de Práctica Clínica, Farmacovigilancia y Tecnovigilancia, del Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) del Seguro Social del Perú (EsSalud), conformó un grupo elaborador de la guía (GEG), que incluyó médicos especialistas y metodólogos.
- Planteamiento de preguntas clínicas: En concordancia con los objetivos y alcances de esta GPC, se formularon las preguntas clínicas.
- Búsqueda de la evidencia para cada pregunta: Para cada pregunta clínica, se realizaron búsquedas de revisiones sistemáticas (publicadas como artículos científicos o guías de práctica clínica). De no encontrar revisiones de calidad, se buscaron estudios primarios, cuyo riesgo de sesgo fue evaluado usando herramientas estandarizadas.
- Evaluación de la certeza de la evidencia: Para graduar la certeza de la evidencia, se siguió la metodología Grading of Recommendations Assessment, Development, and Evaluation (GRADE), y se usaron tablas de Summary of Findings (SoF).
- Formulación de las recomendaciones: El GEG revisó la evidencia recolectada para cada una de las preguntas clínicas en reuniones periódicas, en las que formuló las recomendaciones usando la metodología GRADE, otorgándole una fuerza a cada una. Para ello, se tuvo en consideración los beneficios y daños de las opciones, valores y preferencias de los pacientes, aceptabilidad, factibilidad, equidad y uso de recursos. Estos criterios fueron presentados y discutidos, tomando una decisión por consenso o mayoría simple. Asimismo, el GEG emitió puntos de buenas prácticas clínicas (BPC) sin una evaluación formal de la evidencia, y mayormente en base a su experiencia clínica.
- Revisión externa: La presente GPC fue revisada en reuniones con profesionales representantes de otras instituciones, tomadores de decisiones, y expertos externos.
vacio
vacio
1. SICA ST elevado: diagnóstico
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
En los pacientes con sospecha de síndrome coronario agudo se recomienda que sean evaluados inmediatamente por un profesional de la salud competente y debe realizársele un electrocardiograma de 12 derivaciones. (Recomendación fuerte a favor)
Recomendación 2:
Se sugiere que las concentraciones de troponina se midan al ingreso y 12 horas después del inicio de los síntomas para establecer el pronóstico de infarto de miocardio. (Recomendación condicional a favor)
BPC 1:
Se recomienda que la toma del electrocardiograma se realice e interprete dentro de los primeros 10 minutos de contacto con el médico/llegada al hospital.
BPC 2:
Se recomienda repetir electrocardiogramas de 12 derivaciones si el diagnóstico es incierto o se produce un cambio en el estado del paciente, y antes del alta del hospital.
BPC 3:
En los pacientes con Bloqueo de rama o cambios en el ST persistentes que no cumplan con criterios de SCA se recomienda que se les entregue una copia de su electrocardiograma para ayudar en el manejo clínico futuro si vuelven a presentar un cuadro clínico sospechoso de síndrome coronario agudo.
2. SICA ST elevado: Manejo inicial
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
Los pacientes con síndrome coronario agudo deben tener monitoreo continuo del ritmo cardiaco y proximidad a un desfibrilador. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 2:
En presencia de cambios isquémicos electrocardiográficos, los pacientes con síndrome coronario agudo deben ser tratados inmediatamente con: aspirina (300 mg de dosis carga) y clopidogrel (300 mg de dosis carga para pacientes ˂75 años, 75 mg para pacientes > 75 años), o ticagrelor (180 mg de dosis carga) en quienes se someterán a intervención coronaria percutánea primaria dentro de los 120 minutos desde el diagnostico electrocardiográfico. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 3:
Para los pacientes con síndrome coronario agudo, en quienes los riesgos del uso de ticagrelor (sangrado) superan los beneficios (reducción de recurrencia de eventos aterotrombóticos), se puede considerar aspirina (300 mg de dosis carga) y clopidogrel (300 mg de dosis carga para pacientes ˂75 años, 75 mg para pacientes > 75 años). (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 4:
Debe administrarse aspirina (162 a 325 mg dosis carga) y clopidogrel (300 mg de dosis carga para pacientes ˂75 años, 75 mg para pacientes > 75 años) en pacientes con síndrome coronario agudo ST elevado que reciben terapia fibrinolítica. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 5:
Aspirina debe continuarse indefinidamente y clopidogrel (75 mg diarios) debería continuarse por al menos 14 días en pacientes con síndrome coronario agudo ST elevado que recibió terapia fibrinolítica. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 6:
Los pacientes con SCA ST elevado que reciben terapia de reperfusión o no, deben ser tratados inmediatamente con heparina no fraccionada o heparina de bajo peso molecular. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 7:
Los pacientes con SCA con elevación del ST deberían ser tratados inmediatamente con ICP primaria. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 8:
Deben desarrollarse protocolos locales para el tratamiento rápido de los pacientes que presentan SCA con elevación del ST. Se debe considerar transferir de emergencia a los pacientes hacia centros con capacidad de ICP primaria. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 9:
La implantación del stent coronario debería ser usada en pacientes que reciben ICP. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 10:
La trombectomía no debería ser usada de manera rutinaria durante la ICP primaria. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 11:
Cuando la ICP primaria no puede ser provista dentro de los 120 minutos del diagnóstico electrocardiográfico, los pacientes con SCA con elevación del ST deberían recibir terapia trombolítica inmediata (prehospitalaria o a su admisión). (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 12:
La trombólisis debería ser hecha con un agente fibrino-específico. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 13:
La transferencia a un hospital capaz de realizar ICP para angiografía coronaria es razonable para los pacientes con síndrome coronario agudo ST elevado que recibieron terapia fibrinolítica incluso cuando ya se encuentren hemodinámicamente estables y con evidencia clínica de reperfusión. La angiografía debe realizarse tan pronto sea logísticamente factible en el hospital con capacidad de ICP e idealmente dentro de las primeras 24 horas, pero no debe realizarse en las primeras 3 horas de la administración del trombolítico (estrategia fármacoinvasiva). (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 14:
Los pacientes que presentan SCA ST elevado en quienes la terapia trombolítica es fallida, deberían ser considerados para ICP de rescate y ser transferidos a un centro con capacidad de ICP. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 15:
pacientes con síndrome coronario agudo con elevación del ST tratados con terapia trombolítica exitosa deben ser considerados para angiografía coronaria y revascularización temprana. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 16:
En pacientes con síndrome coronario agudo, el acceso vascular de elección para realizar la ICP debe ser la arteria radial. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 17:
Los pacientes con síndrome coronario agudo confirmado y diabetes mellitus o hiperglicemia marcada (>11.0 mmol/L=200 mg/dl) deben tener un control inmediato de la glucosa con el valor objetivo de 7.0 a 10.9 mmol/L (126 a 196 mg/dl). (Recomendación fuerte a favor, certeza muy baja de la evidencia)
BPC 1:
Los pacientes con síndrome coronario agudo deben ser manejados en un hospital que cuente con capacidad de reperfusión: Intervención Coronaria Percutánea (ICP) o fibrinólisis.
BPC 2:
Ticagrelor no debería ser utilizado como adyuvante de fibrinólisis porque no ha sido estudiado en este escenario.
BPC 3:
La ICP primaria debería ser hecha por el centro con menor tiempo de transferencia para el paciente.
BPC 4:
Todos los centros deberían participar en auditorias constantes de tiempos y retrasos de tratamiento standard relacionado a ICP primaria.
BPC 4:
Los hospitales que adopten la intervención invasiva temprana para los pacientes con síndrome coronario agudo deben considerar el alta precoz en aquellos pacientes con bajo riesgo de eventos subsecuentes.
3. SICA ST elevado: Intervención farmacológica temprana
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
Después del SCA todos los pacientes deben mantenerse en terapia con aspirina a largo plazo. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 2:
Los pacientes con SCA deben recibir tratamiento antiplaquetario doble durante seis meses. Pueden utilizarse períodos más largos cuando los riesgos de acontecimientos aterotrombóticos superan el riesgo de sangrado. Pueden utilizarse períodos más cortos cuando los riesgos de sangrado superan el riesgo de episodios aterotrombóticos. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 3:
Los pacientes con SCA deben comenzar la terapia a largo plazo con estatinas antes del alta hospitalaria (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 4:
Los pacientes con SCA deben mantenerse en terapia con beta-bloqueadores a largo plazo. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 5:
Los pacientes con angina inestable deben comenzar el tratamiento a largo plazo con inhibidores de la enzima convertidora de la angiotensina. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 6:
Los pacientes con infarto de miocardio deben iniciar terapia con inhibidores de la ECA a largo plazo dentro de las primeras 36 horas. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 7:
Los pacientes con infarto de miocardio complicado por disfunción ventricular izquierda o insuficiencia cardíaca que son intolerantes a la terapia con inhibidores de la enzima convertidora de la angiotensina deben iniciar terapia con bloqueadores de receptor de angiotensina a largo plazo. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
Recomendación 8:
Se debe ofrecer evaluación e intervención psicosocial temprana a los pacientes con síndrome coronario agudo, con énfasis en la identificación y manejo de creencias de salud y conceptos cardiacos erróneos. (Recomendación fuerte a favor, certeza muy baja de la evidencia)
BPC 1:
Se recomienda una dosis de 75 a 100 mg de aspirina al día en pacientes con SCA.
BPC 2:
Los nitratos deben utilizarse en pacientes con SCA para aliviar el dolor cardíaco debido a la isquemia miocárdica continua o para tratar la insuficiencia cardíaca aguda.
BPC 3:
La intervención psicosocial forma parte de los programas formales de rehabilitación cardiaca y deben ser vistos como un proceso continuo a lo largo del cuidado del paciente.
4. SICA ST no elevado: diagnóstico
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
En los pacientes con sospecha de síndrome coronario agudo se recomienda que sean evaluados inmediatamente por un profesional de la salud competente y debe realizársele un electrocardiograma de 12 derivaciones. (Recomendación fuerte a favor)
Recomendación 2:
En pacientes con sospecha de síndrome coronario agudo, se sugiere medir las concentraciones de troponina sérica al inicio y a las 12 horas para guiar el manejo y tratamiento apropiados. (Recomendación condicional a favor)
BPC 1:
Se recomienda que la toma del electrocardiograma se realice e interprete dentro de los primeros 10 minutos de contacto con el médico/llegada al hospital.
BPC 2:
Se recomienda repetir electrocardiogramas de 12 derivaciones si el diagnóstico es incierto o se produce un cambio en el estado del paciente, y antes del alta del hospital.
BPC 3:
En los pacientes con Bloqueo de rama o cambios en el ST persistentes que no cumplan con criterios de SCA se recomienda que se les entregue una copia de su electrocardiograma para ayudar en el manejo clínico futuro si vuelven a presentar un cuadro clínico sospechoso de síndrome coronario agudo.
5. SICA ST no elevado: Manejo inicial
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
En personas adultas con exceso de peso y/o factores de riesgo cardiovascular se recomienda intervenciones intensas de asesoramiento conductual para la prevención de ECV. (Recomendación fuerte a favor, certeza moderada de la evidencia)
BCP 1:
Se sugiere realizar las intervenciones intensas de asesoramiento conductual a aquellas personas con los siguientes factores de riesgo: edad avanzada, presión arterial sistólica o diastólica elevada, fumador o exfumador, dislipidemia (colesterol total, LDL, triglicéridos elevados, o HDL disminuido), hipertrofia ventricular izquierda, diabetes mellitus y exceso de peso definido con un índice de masa corporal ≥ 30 Kg/m2 o con una circunferencia abdominal ≥ 102 cm en varones y ≥ 88 en mujeres.
BCP 2:
Se sugiere que la asesoría conductual tenga como objetivo el cambio de comportamientos dirigidos a una dieta saludable y actividad física regular. La asesoría conductual se realizará inicialmente con entrevistas motivacionales personales, complementadas con seguimiento periódico por vía telefónica y debates didácticos y abiertos en grupos pequeños. En ese sentido, la intervención deberá consistir en una educación didáctica, preparación para resolver problemas y dudas, y planes de atención individualizados, considerando la participación también de la familia y/o cuidadores del paciente en la asesoría conductual.
BPC 3:
Se sugiere que las intervenciones sean impartidas por profesionales especialmente capacitados, incluidos dietistas o nutricionistas, fisioterapeutas o profesionales del ejercicio, educadores de salud o psicólogos.
6. SICA ST no elevado: Estrategia invasiva y revascularización
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
En personas adultas con exceso de peso y/o factores de riesgo cardiovascular se recomienda intervenciones intensas de asesoramiento conductual para la prevención de ECV. (Recomendación fuerte a favor, certeza moderada de la evidencia)
BCP 1:
Se sugiere realizar las intervenciones intensas de asesoramiento conductual a aquellas personas con los siguientes factores de riesgo: edad avanzada, presión arterial sistólica o diastólica elevada, fumador o exfumador, dislipidemia (colesterol total, LDL, triglicéridos elevados, o HDL disminuido), hipertrofia ventricular izquierda, diabetes mellitus y exceso de peso definido con un índice de masa corporal ≥ 30 Kg/m2 o con una circunferencia abdominal ≥ 102 cm en varones y ≥ 88 en mujeres.
BCP 2:
Se sugiere que la asesoría conductual tenga como objetivo el cambio de comportamientos dirigidos a una dieta saludable y actividad física regular. La asesoría conductual se realizará inicialmente con entrevistas motivacionales personales, complementadas con seguimiento periódico por vía telefónica y debates didácticos y abiertos en grupos pequeños. En ese sentido, la intervención deberá consistir en una educación didáctica, preparación para resolver problemas y dudas, y planes de atención individualizados, considerando la participación también de la familia y/o cuidadores del paciente en la asesoría conductual.
BPC 3:
Se sugiere que las intervenciones sean impartidas por profesionales especialmente capacitados, incluidos dietistas o nutricionistas, fisioterapeutas o profesionales del ejercicio, educadores de salud o psicólogos.
7. SICA ST no elevado: Intervención farmacológica temprana
Descargar PDF con el desarrollo de la pregunta.
Recomendación 1:
En personas adultas con exceso de peso y/o factores de riesgo cardiovascular se recomienda intervenciones intensas de asesoramiento conductual para la prevención de ECV. (Recomendación fuerte a favor, certeza moderada de la evidencia)
BCP 1:
Se sugiere realizar las intervenciones intensas de asesoramiento conductual a aquellas personas con los siguientes factores de riesgo: edad avanzada, presión arterial sistólica o diastólica elevada, fumador o exfumador, dislipidemia (colesterol total, LDL, triglicéridos elevados, o HDL disminuido), hipertrofia ventricular izquierda, diabetes mellitus y exceso de peso definido con un índice de masa corporal ≥ 30 Kg/m2 o con una circunferencia abdominal ≥ 102 cm en varones y ≥ 88 en mujeres.
BCP 2:
Se sugiere que la asesoría conductual tenga como objetivo el cambio de comportamientos dirigidos a una dieta saludable y actividad física regular. La asesoría conductual se realizará inicialmente con entrevistas motivacionales personales, complementadas con seguimiento periódico por vía telefónica y debates didácticos y abiertos en grupos pequeños. En ese sentido, la intervención deberá consistir en una educación didáctica, preparación para resolver problemas y dudas, y planes de atención individualizados, considerando la participación también de la familia y/o cuidadores del paciente en la asesoría conductual.
BPC 3:
Se sugiere que las intervenciones sean impartidas por profesionales especialmente capacitados, incluidos dietistas o nutricionistas, fisioterapeutas o profesionales del ejercicio, educadores de salud o psicólogos.
Referencias bibliográficas
- Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, Part I. Mayo Clin Proc 2009; 84: 917-38
- Mandelzweig L, Battler A, Boyko V, et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006; 27: 2285-97.
- Yeh RB, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155-65.
- Reyes Rocha M, Heredia Landeo J, Campodonico Hoyos S, Drago Silva J, Alvarado Contreras O. Registro Nacional de Infarto Miocardico Agudo (RENIMA). Rev Per Cardiol 2008; 34: 85-99.
- Reyes Rocha M, Ruiz Mori E, e investigadores RENIMA II. Registro Nacional de Infarto Miocardico Agudo II (RENIMA II). Rev Per Cardiol 2013; 39: 60-71.
- Departmento de Emergencia y Cuidados Criticos. Servicio de Emergencia Adultos. Guía practica clínica para diagnostico y manejo del infarto agudo de miocardio con segmento ST elevado. Hospital Nacional Cayetano Heredia, Lima, 2014. p.1-42
- Documento Técnico: «Metodología para la elaboración de Guías de Práctica Clínica». Lima, Perú: Ministerio de Salud. Dirección General de Salud de las Personas; 2015. p. 1-53
- Directiva para el Desarrollo de Guías de Practica Clínica en EsSalud. Directiva N°02-IETSI-ESSALUD-2016. Disponible en: http://www.essalud.gob.pe/ietsi/guias_pract_clini.html
- Priorizacion de guias de practica clínica EsSalud 2017. Resolucion de Instituto de Evaluación de Tecnologias en Salud e Investigacion N° 13-IETSI-ESSSALUD 2017. Disponible en: http://www.essalud.gob.pe/ietsi/guias_pract_clini.html
- National Clínical Guideline Centre, NICE. Unstable Angina and NSTEMI: the early management of unstable angina and non-ST-segment- elevation myocardial infarction. CG94, 2010.
- Guía de Práctica Clínica Diagnóstico, Estratificación y Tratamiento de pacientes con síndrome coronario agudo sin elevación ST, México; Secretaría de Salud, 2010.
- The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
- Davis T, Bluhm J, Burke R, Iqbal Q, Kim K, Kokoszka M, Larson T, Puppala V, Setterlund L, Vuong K, Zwank M. Institute for Clínical Systems Improvement. Diagnosis and Treatment of Chest Pain and Acute Coronary Syndrome (ACS). http://bit.ly.ACS1112. Updated November 2012.
- Guía de Practica Clínica de Diagnostico y Tratamiento de Infarto Agudo de Miocardio con Elevación del Segmento ST en Mayores de 65 años. México: Secretaria de Salud; 2013.
- Senior JM, Lugo LH, Acosta-Baena N, Saldarriaga CI, Toro JM, Díaz J, Acosta JL, Osío OH, Plata JA, Trespalacios EJ y Equipo de trabajo Guía de Práctica clínica Síndrome Coronario Agudo. Guía de Práctica Clínica para pacientes con diagnóstico de Síndrome Coronario Agudo: Atención inicial y revascularización. Ministerio de Salud y Protección Social, Colciencias, Universidad de Antioquia. Colombia. Guía de práctica clínica-síndrome coronario agudo. Bogotá, 2013. Rev Colomb Cardiol 2013; 20(Supl 2):45-85.
- O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78–140, doi:10.1016/j.jacc.2012.11.019.
- National Clinical Guideline Centre, NICE. Myocardial infarction with ST- segment elevation. The acute management of myocardial infarction with ST-segment elevation. CG167, 2013.
- Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: e139–228.
- Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC), Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2015; 37: 267-315.
- Nikolaou NI, Arntz H-R, Bellou A, et al. European Resuscitation Council Guidelines for Resuscitation 2015 Section 8. Initial management of acute coronary syndromes. Resuscitation 2015; 95: 264-77.
- National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Australian clínical guidelines for the management of acute coronary syndromes 2016. Heart, Lung and Circulation 2016; 25: 895–951.
- Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndrome. Edinburgh: SIGN; 2016. (SIGN publication no. 148). [April 2016]. Available from URL: http://www.sign.ac.uk
- Manual de Adopción de Guías de Práctica Clínica basadas en Evidencia en EsSalud. Lima: EsSalud; 2016. p. 1-31
- GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141(2):190-9.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60(16):1581-98.
- Carruthers KF, Dabbous OH, Flather MD, Starkey I, Jacob A, Macleod D, et al. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart. 2005;91(3):290-8.
- Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345-53.
- Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291(22):2727-33.
- Mant J, McManus RJ, Oakes RA, Delaney BC, Barton PM, Deeks JJ, et al. Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care. Health Technol Assess 2004;8(2):1-158.
- Heidenreich PA, Go A, Melsop KA, Alloggiamento T, McDonals KM, Hagan V, et al. Prediction of risk for patients with unstable angina. Rockville: Agency for Healthcare Research and Quality (US); 2000. [cited 26 Jan 2016]. Available from url: http://www.ncbi.nlm.nih.gov/books/NBK11851/
- Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44(3):E1-E211.
- Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24(1):28-66.
- Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Heart 2001;85(2):133-42.
- Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV Jr, Kirk JD, Smith SC Jr, Gibler WB, Ohman EM, Blomkalns AL, Newby LK, Hochman JS, Peterson ED, Roe MT. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol. 2006 Feb 15;97(4):437-42. Epub 2005 Dec 13. PubMed PMID: 16461033.
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994;343(8893):311-22.
- Go AS, Barron HV, Rundle AC, Ornato JP, Avins AL. Bundle-branch block and in-hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med. 1998;129(9):690-7.
- Holmvang L, Andersen K, Dellborg M, Clemmensen P, Wagner G, Grande P, et al. Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease. Am J Cardiol 1999;83(5):667-74.
- Jernberg T, Lindahl B, Wallentin L. ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction. J Am Coll Cardiol 1999;34(5):1413-9.
- Ganim RP, Lewis WR, Diercks DB, Kirk D, Sabapathy R, Baker L, et al. Right precordial and posterior electrocardiographic leads do not increase detection of ischemia in low-risk patients presenting with chest pain. Cardiology 2004;102(2):100-3.
- Aguiar C, Ferreira J, Seabra-Gomes R. Prognostic value of continuous ST-segment monitoring in patients with non-STsegment elevation acute coronary syndromes. Ann Noninvasive Electrocardiol 2002;7(1):29-39.
- Norgaard BL, Andersen K, Dellborg M, Abrahamsson P, Ravkilde J, Thygesen K. Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia. J Am Coll Cardiol 1999;33(6):1519-27.
- Rosengarten P, Kelly AM, Dixon D. Does routine use of the 15-lead ECG improve the diagnosis of acute myocardial infarction in patients with chest pain? Emerg Med (Fremantle) 2001;13(2):190-3.
- Pelter MM, Adams MG, Drew BJ. Association of transient myocardial ischemia with adverse in-hospital outcomes for angina patients treated in a telemetry unit or a coronary care unit. Am J Crit Care 2002;11(4):318-25.
- Pelliccia F, Cianfrocca C, Marazzi G, Pagliei M, Mariani M, Rosano GM. Continuous 12-lead ST-segment monitoring improves identification of low-risk patients with chest pain and a worse in-hospital outcome. Clin Cardiol 2002;25(2):57-62.
- Lau J, Ioannidis JP, Balk EM, Milch C, Terrin N, Chew PW, et al. Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies. Ann Emerg Med 2001;37(5):453-60.
- Akkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij S, Kint PP, et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J 2001;22(21):1997-2006.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33(20):2551-67.
- Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiol 2001;38(2):478-85.
- Christenson RH, Duh SH, Newby LK, Ohman EM, Califf RM, Granger CB, et al. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem. 1998;44(3):494-501.
- Oltrona L, Ottani F, Galvani M. Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J. 2004;148(3):405-15.
- Information Services Division. Heart Disease Activity. [cited 26 Jan 2016]. Available from url: https://www.isdscotland.org/Health-Topics/Heart-Disease/Publications/2015-01-27/Heart_Disease_discharges_Board_AC1.xls
- Cooper A, Timmis A, Skinner J. Assessment of recent onset chest pain or discomfort of suspected cardiac origin: summary of NICE guidance. BMJ 2010;340:c1118.
- Goodacre S, Thokala P, Carroll C, Stevens JW, Leaviss J, Al Khalaf M, et al. Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome. Health Technol Assess 2013;17(1):1-188.
- Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33(18):2252-7.
- Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ 2015;350:g7873.
- National Institute for Health and Care Excellence. Myocardial Infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays). London: NICE; 2014. [cited 26 Jan 2016]. Available from url: http://www.nice.org.uk/guidance/dg15/resources/myocardial-infarction-acute-earlyrule-out-using-highsensitivity-troponin-tests-elecsys-troponint-highsensitive-architect-stat-high-sensitive-troponini-andaccutni3-assays-1053631469509
- Assessment of high sensitivity cardiac troponin T assay for the rapid diagnosis of acute coronary syndrome and acute myocardial infarction in the emergency room: a review of the clinical and economic evidence 2012. [cited 26 Jan 2016]. Available from url: https://www.cadth.ca/media/pdf/htis/feb-2012/RC0321%20hsTnT%20for%20ACS%20Final.pdf
- Zhelev Z, Hyde C, Youngman E, Rogers M, Fleming S, Slade T, et al. Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and metaanalysis. BMJ 2015;350:h15.
- Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58(11):1574-81.
- Burness CE, Beacock D, Channer KS. Pitfalls and problems of relying on serum troponin. QJM 2005;98(5):365-71.
- Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, et al. Sensitive troponin assay and the classification of myocardial infarction. Am J Med 2015;128(5):493-501.
- McLean S, Wild S, Connor P, Flapan AD. Treating ST elevation myocardial infarction by primary percutaneous coronary intervention, in-hospital thrombolysis and prehospital thrombolysis. An observational study of timelines and outcomes in 625 patients. Emerg Med J 2011;28(3):230-6.
- McLean S, Egan G, Connor P, Flapan AD. Collaborative decisionmaking between paramedics and CCU nurses based on 12-lead ECG telemetry expedites the delivery of thrombolysis in ST elevation myocardial infarction. Emerg Med J 2008;25(6):370-4.
- Dorsch MF, Lawrance RA, Sapsford RJ, Durham N, Das R, Jackson BM, et al. An evaluation of the relationship between specialist training in cardiology and implementation of evidence-based care of patients following acute myocardial infarction. Int J Cardiol 2004;96(3):335-40.
- Jollis JG, DeLong ER, Peterson ED, Muhlbaier LH, Fortin DF, Califf RM, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med 1996;335(25):1880-7.
- Birkhead JS, Weston C, Lowe D. Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-5: observational study. BMJ 2006;332(7553):1306-11.
- Go AS, Rao RK, Dauterman KW, Massie BM. A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States. Am J Med 2000;108(3):216-26.
- Scottish Intercollegiate Guidelines Network. Cardiac arrhythmias in coronary artery disease. Edinburgh: SIGN; 2007. [cited 26 Jan 2016]. Available from url: http://sign.ac.uk/pdf/sign94.pdf
- Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database of Systematic Reviews 2013, Issue 8.
- Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
- American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78-140. doi:10.1016/j.jacc.2012.11.019. Epub 2012 Dec 17. PubMed PMID: 23256914.
- Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110(10):1202-8.
- Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107(7):966-72.
- Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352(12):1179-89.
- Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607-21.
- Brilakis ES, Held C, Meier B, Cools F, Claeys MJ, Cornel JH, et al. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2013;166(3):474-80.
- Clopidogrel, prasugrel and picagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines. 2012. [cited 26 Jan 2016]. Available from url: https://www.cadth.ca/media/pdf/htis/june-2012/RC0360%20Antiplatelets%20for%20ACS%20Final.pdf
- Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375(9711):283-93.
- Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50(19):1844-51.
- Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary síndromes without revascularization. N Engl J Med 2012;367(14):1297-309.
- Steiner S, Moertl D, Chen L, Coyle D, Wells GA. Network metaanalysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost 2012;108(2):318-27.
- Verdoia M, Schaffer A, Barbieri L, Cassetti E, Piccolo R, Galasso G, et al. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol 2014;63(4):339-50.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57.
- Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371(9621):1353-63.
- Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015;372(19):1791-800.
- Guidance on prescribing. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2016. [cited 26 Jan 2016]. Available from url: http://www.evidence.nhs.uk/formulary/ bnf/current/guidance-on-prescribing
- Eikelboom JW, Anand SS, M almberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355(9219):1936-42.
- Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996;313(7058):652-9.
- Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. 1999;100(15):1593-601.
- Magee K, Sevcik WW, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database of Systematic Reviews 2003, Issue 1.
- Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary síndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292(1):45-54.
- Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery síndromes and percutaneous coronary intervention. JAMA 2003;289(3):331-42.
- Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIREThrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105(14):1642-9.
- Baird SH, Menown IB, McBride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23(8):627-32.
- Theroux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 2003;91(7):860-4.
- Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108(2):135-42.
- Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477-88.
- Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. . Lancet 2002;359(9303):294-302.
- White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358(9296):1855-63.
- Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99(20):2626-32.
- Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26(1):57-65.
- de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, et al. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med 2013;173(20):1896-904.
- Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26(7):650-61.
- Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. Health Technol Assess 2005;9(17):1-99.
- Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol Ç, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi:10.1093/eurheartj/ehv320. Epub 2015 Aug 29. PubMed PMID: 26320110.
- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003;361(9351):13-20.
- Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349(8):733-42.
- Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial–PRAGUE-2. Eur Heart J 2003;24(1):94-104.
- Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: A meta-analysis of randomized controlled trials. Am J Med 2004;116(4):253-62.
- Migliorini A, Stabile A, Rodriguez AE, Gandolfo C, Rodriguez Granillo AM, Valenti R, et al. Comparison of AngioJet rheolytic thrombectomy before direct infaECA artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol 2010;56(16):1298-306.
- De Carlo M, Aquaro GD, Palmieri C, Guerra E, Misuraca L, Giannini C, et al. A prospective randomized trial of thrombectomy versus no thrombectomy in patients with ST-segment elevation myocardial infarction and thrombus-rich lesions: MUSTELA (MUltidevice Thrombectomy in Acute ST-Segment ELevation Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2012;5(12):1223-30.
- Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J 2008;29(24):2989-3001.
- Tamhane UU, Chetcuti S, Hameed I, Grossman PM, Moscucci M, Gurm HS. Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for acute ST elevation MI: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2010;10:10.
- Costopoulos C, Gorog DA, Di Mario C, Kukreja N. Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis. Int J Cardiol 2013;163(3):229-41.
- Sobieraj DM, White CM, Kluger J, Tongbram V, Colby J, Chen WT, et al. Systematic review: comparative effectiveness of adjunctive devices in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention of native vessels. BMC Cardiovasc Disord 2011;11:74.
- Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013;369(17):1587-97.
- Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. N Engl J Med 2015;372(15):1389-98.
- Stone GW, Witzenbichler B, Godlewski J, Dambrink JH, Ochala A, Chowdhary S, et al. Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial. Circ Cardiovasc Interv 2013;6(5):527-34.
- Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014;371(12):1111-20.
- Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mota RM, et al. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technol Assess 2003;7(15):1-136.
- Brodie BR, Stone GW, Morice MC, Cox DA, Garcia E, Mattos LA, et al. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001;88(10):1085-90.
- Schomig A, Ndrepepa G, Mehilli J, Schwaiger M, Schuhlen H Nekolla S, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 2003;108(9):1084-8.
- Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33(20):2569-619.
- Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000;283(20):2686-92.
- Bryant M, Kelly AM. “Point of entry” treatment gives best time to thrombolysis for acute myocardial infarction. Aust Health Rev 2001;24(1):157-60.
- Corfield AR, Graham CA, Adams JN, Booth I, McGuffie AC. Emergency department thrombolysis improves door to needle times. Emerg Med J 2004;21(6):676-80.
- McLean S, O’Reilly M, Doyle M, O Rathaille M. Improving Doorto-Drug time and ST segment resolution in AMI by moving thrombolysis administration to the Emergency Department. Accid Emerg Nurs 2004;12(1):2-9.
- Brown N, Melville M, Gray D, Young T, Skene AM, Wilcox RG, et al. Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis. Heart 1999;81(6):598-602.
- Tran CT, Laupacis A, Mamdani MM, Tu JV. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 2004;148(5):834-41.
- Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336(12):847-60.
- Dundar Y, Hill R, Dickson R, Walley T. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM 2003;96(2):103-13.
- De Luca G, Suryapranata H, van’t Hof AWJ, de Boer M, Hoorntje JCA, Dambrink JE, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. 2004;109(22):2737-43.
- Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341(19):1413-9.
- Machecourt J, Bonnefoy E, Vanzetto G, Motreff P, Marliere S, Leizorovicz A, et al. Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: the Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study. J Am Coll Cardiol 2005;45(4):515-24.
- Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004;147(3):457-62.
- de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001;38(5):1283-94.
- Shah PK, Cercek B, Lew AS, Ganz W. Angiographic validation of bedside markers of reperfusion. J Am Coll Cardiol 1993;21(1):55-61.
- Ellis SG, Da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 2000;139(6):1046-53.
- Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353(26):2758-68.
- El-Hayek GE, Gershlick AH, Hong MK, Casso Dominguez A, Banning A, Afshar AE, et al. Meta-Analysis of Randomized Controlled Trials Comparing Multivessel Versus Culprit-Only Revascularization for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention. Am J Cardiol 2015;115(11):1481-6.
- Kowalewski M, Schulze V, Berti S, Waksman R, Kubica J, Kolodziejczak M, et al. Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. Heart 2015;101(16):1309-17.
- Bangalore S, Kumar S, Poddar KL, Ramasamy S, Rha SW, Faxon DP. Meta-analysis of multivessel coronary artery revascularization versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. Am J Cardiol 2011;107(9):1300-10.
- Lagerqvist B, Diderholm E, Lindahl B, Husted S, Kontny F, Stahle E, et al. FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease. Heart 2005;91(8):1047-52.
- Januzzi JL, Jr., Buros J, Cannon CP, Tactics TIMI 18 Investigators. Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. Clin Cardiol 2005;28(5):238-42.
- Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. 2005;366(9489):914-20.
- Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284(7):835-42.
- Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infaECAing myocardium early II trial substudy. Circulation 2000;102(17):2031-7.
- Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101(22):2557-67.
- de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005;26(9):865-72.
- Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of the risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: a prospective multinational observational study (GRACE). BMJ 2006;333(7578):1091.
- Shaw LJ, Peterson ED, Kesler K, Hasselblad V, Califf RM. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol 1996;78(12):1327-37.
- Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107(22):2786-92.
- Carluccio E, Tommasi S, Bentivoglio M, Buccolieri M, Prosciutti L, Corea L. Usefulness of the severity and extent of wall motion abnormalities as prognostic markers of an adverse outcome after a first myocardial infarction treated with thrombolytic therapy. Am J Cardiol 2000;85(4):411-5.
- Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15(1):79-87.
- Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293(23):2908-17.
- Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354(9180):708-15.
- Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a noninvasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356(9223):9-16.
- Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879-87.
- Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Randonized Intervention Trial of unstable Angina. Lancet 2002;360(9335):743-51.
- de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353(11):1095-104.
- Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89(4):1545-56.
- Boden WE, O’Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al. Outcomes in patients with acute non-Qwave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338(25):1785-92.
- Spacek R, Widimsky P, Straka Z, Jiresova E, Dvorak J, Polasek R, et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J 2002;23(3):230-8.
- Michalis LK, Stroumbis CS, Pappas K, Sourla E, Niokou D, Goudevenos JA, et al. Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery. Invasive versus conservative strategy (TRUCS study). Eur Heart J 2000;21(23):1954-9.
- McCullough PA, O’Neill WW, Graham M, Stomel RJ, Rogers F, David S, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol 1998;32(3):596-605.
- Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003;42(4):634-41.
- Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, Vazquez N, Blanco J, Alonso-Briales J, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004;364(9439):1045-53.
- Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46(3):417-24.
- Thiele H, Engelmann L, Elsner K, Kappl MJ, Storch WH, Rahimi K, et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005 26(19):1956-63.
- Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26(8):804-47.
- De Luca G, Schaffer A, Wirianta J, Suryapranata H. Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. Int J Cardiol 2013;168(3):2070-81.
- Karrowni W, Vyas A, Giacomino B, Schweizer M, Blevins A, Girotra S, et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2013;6(8):814-23.
- Singh PP, Singh M, Khosla N, Shah T, Molnar J, Arora R, et al. Safety and efficacy of transradial versus transfemoral percutaneous coronary intervention in acute myocardial infarction: a metaanalysis of randomized trials. Coron Artery Dis 2012;23(4):284-93.
- Vorobcsuk A, Konyi A, Aradi D, Horvath IG, Ungi I, Louvard Y, et al. Transradial versus transfemoral percutaneous coronary intervention in acute myocardial infarction Systematic overview and meta-analysis. Am Heart J 2009;158(5):814-21.
- Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015;385(9986):2465-76.
- Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary síndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377(9775):1409-20.
- Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. JAMA 2013;310(19):2086-95.
- Birim O, Bogers AJ, Kappetein AP. Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting. J Cardiovasc Surg (Torino) 2012;53(5):641-50.
- Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109(9):1114-20.
- Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6921):81-106.
- Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004;8(40):1-141.
- Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33(24):3078-87.
- Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385(9985):2371-82.
- Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350(h1618).
- Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess 2009;13(31):1-77.
- Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60.
- Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282(21):2058-67.
- Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143(4):241-50.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7.
- Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349-57.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
- Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129(9):681-9.
- Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357(9262):1063-8.
- Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96(5):611-6.
- Saab FA, Eagle KA, Kline-Rogers E, Fang J, Otten R, Mukherjee D. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. Am J Cardiol 2004;94(9):1166-8.
- de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16.
- Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-8.
- Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006;295(17):2046-56.
- Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260(15):2259-63.
- Scottish Intercollegiate Guidelines Network. Management of chronic heart failure. Edinburgh: SIGN; 2016. [cited 18 Mar 2016]. Available from url: www.sign.ac.uk/pdf/SIGN147.pdf
- Stone PH, Gibson RS, Glasser SP, DeWood MA, Parker JD, Kawanishi DT, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation 1990;82(6):1962-72.
- Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17(1):104-12.
- Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318(7200):1730-7
- Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357(9266):1385-90.
- ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of InfaECA Survival) Collaborative Group. Lancet 1995;345(8951):669-85.
- GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994;343(8906):1115-22.
- The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988;319(7):385-92.
- Vaage-Nilsen M, Rasmussen V, Hansen JF, Hagerup L, Sorensen MB, Pedersen-Bjergaard O, et al. Prognostic implications of ventricular ectopy one week, one month, and sixteen months after an acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction. Clin Cardiol 1998;21(12):905-11.
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53.
- Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-8.
- Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058-68.
- Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97(22):2202-12.
- Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355(9215):1575-81.
- Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360(9335):752-60.
- Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906.
- Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66.
- Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6.
- McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71.
- Cossette S, Frasure-Smith N, Lesperance F. Clinical implications of a reduction in psychological distress on cardiac prognosis in patients participating in a psychosocial intervention program. Psychosom Med 2001;63(2):257-66.
- Scottish Intercollegiate Guidelines Network. Cardiac rehabilitation. Edinburgh: SIGN; 2002. [cited 27 Jan 2016]. Available from url:http://www.sign.ac.uk
- Simmonds RL, Tylee A, Walters P, Rose D. Patients’ perceptions of depression and coronary heart disease: a qualitative UPBEAT-UK study. BMC Fam Pract 2013;14:38.
- Thompson DR. A randomized controlled trial of in-hospital nursing support for first time myocardial infarction patients and their partners: effects on anxiety and depression. J Adv Nurs 1989;14(4):291-7.
- Petrie KJ, Cameron LD, Ellis CJ, Buick D, Weinman J. Changing illness perceptions after myocardial infarction: an early intervention randomized controlled trial. Psychosom Med 2002;64(4):580-6.
- Johnston M, Foulkes J, Johnston DW, Pollard B, Gudmundsdottir H. Impact on patients and partners of inpatient and extended cardiac counseling and rehabilitation: a controlled trial. Psychosom Med 1999;61(2):225-33.
Si tienes comentarios sobre el contenido de las guías de práctica clínica, puedes comunicarte con IETSI-EsSalud enviando un correo a ietsi.gpc@gmail.com
SUGERENCIAS
Si has encontrado un error en esta página web o tienes alguna sugerencia para su mejora, puedes comunicarte con EviSalud enviando un correo a evisalud@gmail.com